Browse studies

Find your next paid study

639 recruiting studies matching your filters

ADEPT: Augmenting DBT Effectiveness With Psilocybin-Assisted Therapy

ADEPT is an open-label proof-of-concept study evaluating the safety and tolerability of psilocybin-assisted therapy in conjunction with Dialectical Behavior Th…

Borderline Personality DisorderBorderline Personality PathologyDepressive Symptoms+2 more

Estimated

~$10 – $6,250

University of MinnesotaNCT07833761

Phase 2

A Phase II Trial of Trifluridine/Tipiracil Plus Oxaliplatin in Patients With Advanced or Metastatic Biliary Tract Cancer Following First-Line Therapy

Participants are eligible for this study who were treated for advanced biliary tract cancer (BTC) but the treatment either did not make the cancer better or is…

Biliary Tract CancerBiliary Tract NeoplasmsCholangiocarcinoma+2 more

Estimated

~$10 – $6,250

Case Comprehensive Cancer CenterNCT07146646

Phase 3

A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)

The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment f…

Breast NeoplasmsNeoplasm Metastasis

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07174336

Phase 1

A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)

This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a p…

Ovarian NeoplasmsBreast NeoplasmsPancreatic Intraductal Neoplasms+4 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07213791

Molecular Basis of Human Phagocyte Interactions With Bacterial Pathogens

Human phagocytic cells such as polymorphonuclear leukocytes (PMNs) are readily mobilized to sites of infection and ingest microorganisms by a process known as …

Host Defense Mechanisms

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT00339287

Phase 3

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis

Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and sa…

Multiple Sclerosis (MS) Primary Progressive

Estimated

~$10 – $8,750

Zenas BioPharma (USA), LLCNCT07067463

Defining the Brain Phenotype of Children With 7q11.23 Copy Number Variation, Including Williams Syndrome and 7q11.23 Duplication Syndrome

Background: \- Little is known about how the brain changes during childhood and adolescence, how genes affect this process, or how the brains of people with 7…

Williams SyndromeDuplication

Estimated

~$10 – $675

National Institute of Mental Health (NIMH)NCT01132885

Observational

Empowering Patients' Lung Cancer Screening Uptake (Empower LCS/Call+): A Multi-Site Pilot Randomized Controlled Trial

Lung cancer screening (LCS) with low-dose computed tomography (LDCT) can reduce the risk of dying from lung cancer, but many people who are eligible for screen…

Lung Cancer ScreeningLung NeoplasmsSmoking ( Cigarette)+1 more

Estimated

~$10 – $6,250

University of California, IrvineNCT07711691

Phase 1

A Phase 1/1b Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 436 as Monotherapy and in Combination With Other Therapies in Participants With Microsatellite Instability-high (MSI-H)/Mismatch Repair Deficient (dMMR) Solid Tumors

The primary objectives of this trial are to evaluate the safety profile of AMG 436 and to determine the maximum tolerated dose (MTD) and/or the recommended dos…

Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

Background: High-risk blood cancers (leukemias and lymphomas) often come back after treatment, and many cannot be cured with chemotherapy alone. These cancers…

Hematologic MalignanciesHematologic Neoplasms

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07162038

Phase 2

Metronomic Decitabine-Cedazuridine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia R/R AML), High Risk Myelodysplastic Syndrome (HR-MDS), and High-Risk Myeloproliferative Neoplasms (HR/AP MPN)

This is a single-center randomized phase 2 open-label clinical trial.

Relapsed / Refractory AMLHigh Risk Myelodysplastic SyndromeHigh Risk Myeloproliferative Neoplasms

Estimated

~$10 – $6,250

Virginia Commonwealth UniversityNCT07710534

Phase 1

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Enrichment, and Dose-Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BLU-924 (SAR449336) as Monotherapy and Combination Therapy in Participants With Advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Harboring KRAS Mutations

A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in particip…

Advanced Solid TumorNon-Small Cell Lung CancerColorectal Neoplasms+1 more

Estimated

~$10 – $8,750

Blueprint Medicines CorporationNCT07629960